Prognostic Factors for Gefitinib-Treated Postoperative Recurrence in Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1423-0232|72|3-4|234-242

ISSN： 0030-2414

Source： Oncology, Vol.72, Iss.3-4, 2008-01, pp. : 234-242

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 509-513

Karger

Access to resources Recommend Favorite

Recurrence and Risk Factors for Relapse in Patients with Non-Small Cell Lung Cancer Treated by Surgery with Curative Intent

By  

Oncology, Vol. 92, Iss. 6, 2017-03 ,pp. : 347-352

Karger

Access to resources Recommend Favorite

Prognostic Factors in Elderly Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 355-362

Karger

Access to resources Recommend Favorite

The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer

By Suzuki Takeshi   Mitsudomi Tetsuya   Hida Toyoaki  

Personalized Medicine, Vol. 1, Iss. 1, 2004-12 ,pp. : 27-34

Future Medicine

Access to resources Recommend Favorite

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

By  

Oncology, Vol. 79, Iss. 5-6, 2011-04 ,pp. : 423-429

Karger

Access to resources Recommend Favorite